PACLITAXEL RESPONSE MARKERS FOR CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 27, 2014
app pub date -
Nov 27, 2012
filing date -
Nov 28, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Cancer marker sets consisting of particular genes differentially expressed in tumours provide improved accuracy of predicting effectiveness of paclitaxel or paclitaxel-like drug treatment against a cancer. These sets are further useful for screening drug candidates for paclitaxel-like cancer treatment activity. The cancer marker sets may be used in a clinical setting to provide information about the likelihood that a cancer patient would or would not respond to paclitaxel or paclitaxel-like drug treatment.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully